Corient Private Wealth LLC Acquires 390,000 Shares of Nautilus Biotechnology, Inc. $NAUT

Corient Private Wealth LLC lifted its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 860.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 435,350 shares of the company’s stock after buying an additional 390,000 shares during the period. Corient Private Wealth LLC owned approximately 0.34% of Nautilus Biotechnology worth $316,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NAUT. Clarius Group LLC lifted its stake in Nautilus Biotechnology by 22.4% during the 2nd quarter. Clarius Group LLC now owns 1,060,460 shares of the company’s stock valued at $769,000 after acquiring an additional 193,874 shares during the period. Jane Street Group LLC lifted its position in Nautilus Biotechnology by 304.1% during the second quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock valued at $210,000 after purchasing an additional 218,512 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Nautilus Biotechnology during the first quarter valued at approximately $194,000. Y Intercept Hong Kong Ltd purchased a new stake in Nautilus Biotechnology in the second quarter worth approximately $163,000. Finally, Nuveen LLC bought a new stake in Nautilus Biotechnology in the 1st quarter worth approximately $167,000. 50.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NAUT. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Sell” and a consensus target price of $2.50.

Nautilus Biotechnology Price Performance

NASDAQ:NAUT opened at $1.91 on Wednesday. Nautilus Biotechnology, Inc. has a one year low of $0.62 and a one year high of $2.54. The business has a fifty day moving average price of $1.85 and a 200-day moving average price of $1.15. The firm has a market capitalization of $241.25 million, a price-to-earnings ratio of -3.82 and a beta of 1.48.

Nautilus Biotechnology (NASDAQ:NAUT) last released its earnings results on Monday, October 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. On average, equities research analysts expect that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Nautilus Biotechnology Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.